President Abdel-Fattah El-Sisi said that the government aims to provide safe medicine at an affordable price to all citizens and will continue to develop the capacities of producing all necessary drugs locally according to the highest international standards.
The president's remark came during the inauguration on Thursday of the Egyptian medical city GYPTO Pharma, which has been established with state-of-the-art technology.
“We started preparing for this project seven years ago. It took time because we wanted to ensure the highest international standards for the medicine we produce,” El-Sisi explained.
“We will complete the factory to produce plasma in two years. We are realising a dream. We have the human resources, represented in our large population, to accomplish this,” he said.
The president also stressed that “we will do our utmost to produce our own components for the drugs that we produce locally."
The president explained that “the government aims to produce cancer medication and other very important drugs in the coming period.”
El-Sisi said the new project aims to manufacture drugs with potent active ingredients in order to be on par with their alternatives produced in all developed countries.
"I got upset when some said that we should get antibiotics from abroad due to the potency of their active substance," adding that "the efficacy of the products produced at the city would not be 99.9 percent, but 100 percent effective," he added.
Prime Minister Mostafa Madbouly attended the inauguration event alongside Defence Minister Mohamed Zaki and a number of ministers and senior officials.
After opening remarks, the president toured the facilities and listened to reports from staff on work at the giant plant.
A medical giant
GYPTO Pharma will be one of the state's arms to produce safe and effective medication at suitable prices for Egyptian citizens.
The 180,000-square-metre city, which is located in El-Khanka, Qalioubiya, is considered the largest pharmaceutical production hub in the Middle East.
GYPTO Pharma consists of standalone utility buildings that serve its main production plant.
Due to its importance, the city project was designed, executed, and validated according to the latest health and safety standards.
The new city's immense capabilities will help serve the massive Egyptian market with superior and affordable local medication.
GYPTO Pharma is intended to up cooperation between the state and the private sector to make Egypt a regional center for manufacturing medication in the Middle East.
Strategic reserves and health initiatives
In remarks at the start of the event, PM Madbouly said that the country's strategic reserves of medicines will suffice for three months.
Egypt now possesses 1.6 million doses of coronavirus vaccines, Madbouly said.
The premier explained that Egypt produces all supplies needed to deal with the coronavirus locally with only one exception.
He added that the government is providing the necessary amounts of medical oxygen to deal with the pandemic.
“The country's reserves of medical oxygen are safe,” Madbouly said.
“We have reached 88 percent in local production of medicine,” he added.
The new Egyptian medical city is a giant establishment by all international standards, Madbouly stressed.
It was built as part of the state's comprehensive vision to achieve a qualitative leap in the health of citizens, he added.
The construction of the city is part of the state's efforts to improve public health in tandem with various presidential initiatives such as the 100 Million Lives Initiative, the Women's Health Initiative, and the initiative to end waiting lists, Madbouly said.
Tamer Essam, the head of the Egyptian Drug Authority (EDA), expressed in remarks during the inauguration hope that the new city would work according to the highest level of international standards.
He stated that a firm specialised in manufacturing oncology related medicinal products and immunosuppressive products will be established in Egypt soon.
Speaking on the EDA's monthly performance rates, he said it evaluates up to 1,500 products and pharmaceutical files, in addition to reviewing 2,000 studies and samples.
As for the coronavirus pandemic, Essam said Egypt is the first country in the Middle East to manufacture the drugs used in coronavirus treatment protocols and is among the first countries that licensed COVID-19 vaccines for emergency use.
Meanwhile, Omar Mamdouh, the CEO of GYPTO Pharma, presented to the president on the various operation phases and the latest technology used in the production at the complex.
Concerning marketing efforts, Mamdouh said the packaging of drugs will be carried out in a way that reflects the quality of the product so that they may be delivered to Egyptians in the best manner.
Concerning marketing efforts, the EDA head said the packaging of drugs will be carried out in a way that reflects the quality of the product so that they may be delivered to Egyptians in the best manner.